Abstract
Myocardial perfusion imaging (MPI) using advanced PET technology is increasingly used for non-invasive detection and evaluation of coronary artery disease (CAD), but is still limited for clinical use. Recently, 18F labeled PET perfusion tracers have been actively developed as a novel class of PET MPI agents to overcome the disadvantages of conventional PET MPI tracers (15O-labelled water, 13N-ammonia, and 82Rb chloride). This review summarizes the advantages and the feasibility of recent developed 18F labeled tracers in clinical practice.